India approves human trials for second Covid-19 vaccine candidate

accreditation
  • A Covid-19 vaccine contender is to undergo human studies in India.
  • Zydus developed the potential vaccine .
  • There were no initial safety concerns with the new drug.


Indian regulators have granted Zydus approval to begin human studies for its Covid-19 vaccine contender, the drug maker said on Friday, as the novel coronavirus infections continue to surge in the world's fourth worst-hit nation.

LIVE | All the latest coronavirus and lockdown updates

The potential vaccine showed a "strong immune response" in animal studies, and the antibodies produced were able to completely neutralise the wild type virus, Zydus, part of Cadila Healthcare Ltd, said in a statement to Indian stock exchanges.

India's approval for Zydus comes days after privately held Bharat Biotech got a similar green light for human studies for its vaccine candidate.

Zydus will begin human trials this month in over 1 000 subjects in multiple sites in India, it said. The company also plans to ramp up its production capacity for the vaccine contender to serve Indian and global demand, it added.

There were no safety concerns for the vaccine candidate in repeat dose toxicology studies, Zydus said. In rabbits, up to three times the intended human dose was found to be safe, well tolerated and immunogenic.

No vaccine has yet been approved for commercial use against Covid-19, but more than a dozen from over 100 candidates globally are currently being tested in humans, and some have shown potential in early-stage trials.

The number of coronavirus infections in India surpassed 600 000 on Thursday, resulting in 17 834 deaths as authorities battled to contain the pandemic while easing lockdown rules.

Only the US, Brazil and Russia have reported more cases than India.

Stay healthy and entertained during the national lockdown. Sign up for our Lockdown Living newsletter. Sign up and manage your newsletters in the new News24 app by clicking on the Profile tab

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For only R75 per month, you have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today.
Subscribe to News24
Lockdown For
DAYS
HRS
MINS
Voting Booth
Children between 12 and 17 can now be vaccinated against Covid-19. As a parent I am:
Please select an option Oops! Something went wrong, please try again later.
Results
Relieved, it's been a long wait to this point
50% - 2224 votes
A bit hesitant, and will wait to see how it goes
22% - 976 votes
Completely against my child getting the shot
28% - 1251 votes
Vote
Rand - Dollar
14.63
+0.5%
Rand - Pound
20.16
+0.5%
Rand - Euro
17.03
+0.4%
Rand - Aus dollar
10.96
-0.0%
Rand - Yen
0.13
+0.4%
Gold
1,793.33
+0.6%
Silver
24.35
+0.8%
Palladium
2,042.50
+1.2%
Platinum
1,065.00
+1.2%
Brent Crude
84.61
-1.4%
Top 40
60,024
+1.0%
All Share
66,570
+0.8%
Resource 10
62,180
+1.4%
Industrial 25
86,128
+0.8%
Financial 15
13,855
+0.3%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE